For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...
This means mothers whose babies need antibiotics could leave hospital sooner and complete treatment at home with full clinical support, potentially reducing their hospital stay by up to 2.7 days. All ...
The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...
There is a commercial access agreement for semaglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...
There is a simple discount patient access scheme for zanidatamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
NICE is unable to make a recommendation on oxybutynin hydrochloride (Vesoxx) for managing neurogenic detrusor overactivity. This is because the company did not provide an evidence submission.
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on ...
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...
This guidance has been updated and replaced by NICE guideline CG182 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results